HRTXHeron Therapeutics Inc
−6.7% today · −74.8% over a year
No score: too little data.
No dividend.
Heron Therapeutics Inc (HRTX) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €47.4M. Over the past 12 months the price changed by −74.8%, with an annualised volatility of 104% and a largest fall of 82%. Hard red flags in our rules-based screen: Heavy dilution, Financial distress.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Red flags and notes
- Serious warning. Share count growing more than 10 % a year over three years. More in the glossary → Share count growing more than 10 % a year over three years.
- Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Below $1 Price below one US dollar: not ranked against peers.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 9.1
- P/S
- 0.4
- Free-cash-flow yield
- −22.8%
- Market cap (EUR)
- €47.4M
Profitability and debt
- Return on invested capital
- −54.0%
- Gross margin
- 70.1%
Dividends
- Dividend yield
- 0.00%
- Years without a lower dividend
- 0
Returns and risk
- 1 day
- −6.7%
- 1 month
- −24.3%
- 1 year
- −74.8%
- Volatility, 1 yr
- 103.7%
- Max drawdown, 1 yr
- −81.9%
- Beta
- 1.38
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| SKINSkinHealth Systems | 2/10 | 0.0% | −64.8% |
|---|---|---|---|
| ATRAAtara Biotherapeutics Inc | —/10 | 0.0% | −26.0% |
| VXRTVaxart Inc | —/10 | 0.0% | 12.1% |
| FRNMFreenome Inc. | —/10 | 0.0% | −2.4% |
| LENZLENZ Therapeutics, Inc. | 1/10 | 0.0% | −86.0% |
| BDTXBlack Diamond Therapeutics Inc | —/10 | 0.0% | −57.1% |
| AVXLAnavex Life Sciences Corp. | —/10 | 0.0% | −84.8% |
| BYSIBeyondSpring | —/10 | 0.0% | −67.6% |
News and filings
- HERON THERAPEUTICS, INC. /DE/: 8-K — Material agreement
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 29 Sep 2026
- HERON THERAPEUTICS, INC. /DE/: 8-K — Material agreement; change to security holders' rights
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 14 Aug 2026
- HERON THERAPEUTICS, INC. /DE/: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 10 Aug 2026
- HERON THERAPEUTICS, INC. /DE/: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 10 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.